About this Journal Submit a Manuscript Table of Contents
ISRN Urology
Volume 2013 (2013), Article ID 863489, 8 pages
http://dx.doi.org/10.1155/2013/863489
Clinical Study

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia

1Department of Urology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan
2Department of Pathology, Kanto Rosai Hospital, 1-1 Kizukisumiyoshi-cho, Nakahara-ku, Kawasaki 211-8510, Japan

Received 29 November 2012; Accepted 19 December 2012

Academic Editors: C. E. Constantinou, J. H. Ku, and R. Shamloul

Copyright © 2013 Masayoshi Zaitsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. D. Wilson, “Role of dihydrotestosterone in androgen action,” The Prostate, supplement 6, pp. 88–92, 1996. View at Scopus
  2. Clinical guideline of benign prostatic hyperplasia of American Urological Association, http://www.auanet.org.
  3. D. W. Russell and J. D. Wilson, “Steroid 5 alpha-reductase: two genes/two enzymes,” Annual Review of Biochemistry, vol. 63, pp. 25–61, 1994.
  4. G. Andriole, N. Bruchovsky, L. W. K. Chung et al., “Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia,” Journal of Urology, vol. 172, no. 4 I, pp. 1399–1403, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. R. V. Clark, D. J. Hermann, G. R. Cunningham, T. H. Wilson, B. B. Morrill, and S. Hobbs, “Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 5, pp. 2179–2184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Keam and L. J. Scott, “Dutasteride: a review of its use in the management of prostate disorders,” Drugs, vol. 68, no. 4, pp. 463–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. A. E. Thigpen, K. M. Cala, and D. W. Russell, “Characterization of Chinese hamster ovary cell lines expressing human steroid 5α-reductase isozymes,” Journal of Biological Chemistry, vol. 268, no. 23, pp. 17404–17412, 1993. View at Scopus
  8. M. Marberger, “Drug insight: 5α-reductase inhibitors for the treatment of benign prostatic hyperplasia,” Nature Clinical Practice Urology, vol. 3, no. 9, pp. 495–503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. V. Frye, “Discovery and clinical development of dutasteride, a potent dual 5α-reductase inhibitor,” Current Topics in Medicinal Chemistry, vol. 6, no. 5, pp. 405–421, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. H. N. Bramson, D. Hermann, K. W. Batchelor, F. W. Lee, M. K. James, and S. V. Frye, “Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR,” Journal of Pharmacology and Experimental Therapeutics, vol. 282, no. 3, pp. 1496–1502, 1997. View at Scopus
  11. A. V. Sarma and J. T. Wei, “Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms,” New England Journal of Medicine, vol. 367, pp. 248–257, 2012.
  12. R. G. Hahn, T. Fagerström, T. L. J. Tammela et al., “Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride,” British Journal of Urology International, vol. 99, no. 3, pp. 587–594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Kravchick, S. Cytron, A. Mamonov, R. Peled, and L. Linov, “Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study,” Urology, vol. 73, no. 6, pp. 1274–1278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. H. Ku, J. K. Shin, M. C. Cho, J. K. Myung, K. C. Moon, and J. S. Paick, “Effect of dutasteride on the expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in rat and human prostate tissue,” Scandinavian Journal of Urology and Nephrology, vol. 43, no. 6, pp. 445–453, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. P. J. Gallagher and A. C. van der Wal, “Blood vessels,” in Histology for Pathologists, S. E. Mills, Ed., pp. 217–238, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 3rd edition, 2007.
  16. J. Wilting, M. Papoutsi, B. Christ et al., “The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues,” The FASEB Journal, vol. 16, no. 10, pp. 1271–1273, 2002. View at Scopus
  17. U. Fiedler, S. Christian, S. Koidl et al., “The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors,” American Journal of Pathology, vol. 168, no. 3, pp. 1045–1053, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. http://www.merriam-webster.com/medical/microvessel.
  19. A. Godoy, A. Watts, P. Sotomayor et al., “Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell,” Endocrinology, vol. 149, no. 6, pp. 2959–2969, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Shabsigh, D. T. Chang, D. F. Heitjan et al., “Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival,” Prostate, vol. 36, no. 3, pp. 201–206, 1998. View at Publisher · View at Google Scholar
  21. J. F. Donohue, D. Hayne, U. Karnik, D. R. Thomas, and M. C. Foster, “Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks,” British Journal of Urology International, vol. 96, no. 9, pp. 1319–1322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. G. Lekas, A. C. Lazaris, M. Chrisofos et al., “Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia,” Urology, vol. 68, no. 2, pp. 436–441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. K. R. Butler Jr., H. Benghuzzi, M. Tucci, and A. Puckett, “Neovascularization is influenced by androgenic hormones in the tissue implant response,” Biomedical Sciences Instrumentation, vol. 48, pp. 49–56, 2012.
  24. K. Røe, L. T. Mikalsen, A. J. van der Kogel, et al., “Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer,” Radiation Oncology, vol. 7, no. 1, article 75, 2012. View at Publisher · View at Google Scholar
  25. K. Das, P. D. N. Lorena, L. K. Ng et al., “Differential expression of steroid 5α-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer,” Endocrine-Related Cancer, vol. 17, no. 3, pp. 757–770, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. G. L. Andriole, P. Humphrey, P. Ray et al., “Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer,” Journal of Urology, vol. 172, no. 3, pp. 915–919, 2004. View at Publisher · View at Google Scholar
  27. G. L. Andriole, D. G. Bostwick, O. W. Brawley et al., “Effect of dutasteride on the risk of prostate cancer,” New England Journal of Medicine, vol. 362, no. 13, pp. 1192–1202, 2010. View at Publisher · View at Google Scholar · View at Scopus